Adalimumab originator and biosimilars in global inflammatory bowel disease treatment

被引：0
|
作者：
Yiu, Tsz Hong [1 ]
Nakase, Hiroshi [3 ]
Leung, Wai Keung [4 ]
Lin, Huiyu [5 ]
Banerjee, Rupa [6 ,7 ]
Anderson, Emilia [2 ]
Leong, Rupert [2 ]
机构：
[1] Western Hlth, Melbourne, Vic, Australia
[2] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[3] Sapporo Med Univ, Sapporo, Hokkaido, Japan
[4] Univ Hong Kong, Pok Fu Lam, Hong Kong, Peoples R China
[5] Tan Tock Seng Hosp, Singapore, Singapore
[6] Asian Inst Gastroenterol, Gachibowli, India
[7] AIG Hosp, Gachibowli, India
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2024年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
101
引用
收藏
页码：173 / 174
页数：2
相关论文
共 50 条
  • [31] Adalimumab for treatment of very early onset inflammatory bowel disease
    Xie, Yao
    Liu, Li-Li
    Jiang, Yi
    Tang, Ze-Zhong
    Sun, Guo-Yu
    Hou, Xin-Lin
    CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2889 - 2890
  • [32] Evolutionary Features of Adalimumab Treatment in Patients with Inflammatory Bowel Disease
    Ovidiu, Fratila
    Gabriela, Cioca
    Tiberia, Ilias
    XXXVI NATIONAL CONGRESS OF GASTROENTEROLOGY, HEPATOLOGY AND DIGESTIVE ENDOSCOPY, 2016, : 178 - 185
  • [33] Adalimumab for treatment of very early onset inflammatory bowel disease
    Xie Yao
    Liu LiLi
    Jiang Yi
    Tang ZeZhong
    Sun GuoYu
    Hou XinLin
    中华医学杂志英文版, 2019, 132 (23) : 2889 - 2890
  • [34] Efficacy and safety of adalimumab in the treatment of inflammatory bowel disease in children
    De Caro, G.
    Madia, C.
    Gaiani, F.
    Fugazza, A.
    Bizzarri, B.
    Ghiselli, A.
    Fornaroli, F.
    Vincenzi, F.
    de' Angelis, G. L.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S374 - S375
  • [35] Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel Disease
    Deprez, N.
    De Somer, T.
    Baert, D.
    Deceuninck, M.
    Huys, I.
    Mattens, V.
    Sterckx, A.
    Vanden Branden, S.
    Vanderstraeten, E.
    Vandervoort, J.
    Vanheddegem, N.
    Dewint, P.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S314 - S315
  • [36] Effectiveness and safety of Adalimumab Biosimilars in Bio-naive patients with Inflammatory Bowel Disease: The Galician experience
    Villaamil, P. Vega
    Rey, M. T. Vazquez
    Rey, I. Baston
    Galego, M. Ayude
    Campos, A. Carmona
    Lopez, A. M. Baz
    Arriero, G. Molina
    Barcia, M. J. Ruiz
    Exposito, C. Regueiro
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1622 - I1622
  • [37] Adalimumab in Pediatric Inflammatory Bowel Disease
    Choi, So Yoon
    Kang, Ben
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [38] A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
    Barberio, Brigida
    Cingolani, Linda
    Canova, Cristina
    Barbieri, Giulia
    Sablich, Renato
    Urbano, Maria Teresa
    Bertani, Lorenzo
    Costa, Francesco
    Bodini, Giorgia
    Demarzo, Maria Giulia
    Ferronato, Antonio
    Buda, Andrea
    Melatti, Piera
    Massimi, Davide
    Savarino, Edoardo Vincenzo
    Zingone, Fabiana
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [39] Adalimumab biosimilar in inflammatory bowel disease
    Fiorino, Gionata
    Allocca, Mariangela
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 775 - 776
  • [40] Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
    Annese, Vito
    Vecchi, Maurizio
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (11) : 963 - 968
12345